The Nigeria Infectious Disease In-vitro Diagnostics Market size is projected to reach US$ 59.67 million by 2031 from US$ 41.04 million in 2024. The market is estimated to register a CAGR of 5.5% during 2024–2031. Technological advancements are likely to bring new Nigeria Infectious Disease In-vitro Diagnostics Market trends in the coming years.
The Nigerian in-vitro diagnostics (IVD) market for infectious diseases is expanding due to several key drivers and emerging opportunities. The rising prevalence of infectious diseases, such as Lassa fever, HIV, and malaria, necessitates timely and accurate diagnostic solutions. This demand is further supported by government initiatives like the National Health Insurance Scheme (NHIS), which enhances accessibility to diagnostic services. Technological advancements, particularly in point-of-care testing (POCT) and molecular diagnostics, are pivotal in providing rapid and precise results, crucial for effective disease management in resource-limited settings. Integrating artificial intelligence (AI) and machine learning (ML) into diagnostic processes also revolutionizes data analysis, leading to more accurate and personalized disease detection. These developments present significant opportunities for stakeholders to invest in innovative diagnostic technologies that cater to the growing healthcare needs of Nigeria's population.
Key players are focusing on boosting local manufacturing capacity, fostering innovation, and reducing dependency on imported diagnostic products. In May 2025, Codix Pharma Ltd, a Nigerian pharmaceutical firm, commissioned Codix Bio Ltd, an IVD manufacturing facility in Sagamu, Ogun State. This facility, the first in Nigeria and the second in sub-Saharan Africa, is expected to produce over 147 million rapid diagnostic test kits annually for malaria, HIV, and hepatitis B and C. This development addresses the need for timely, affordable, locally produced diagnostics, especially for underserved populations. Such initiatives strengthen healthcare independence, improve disease surveillance, and propel market growth.
As of May 2025, there are 937 Diagnostic centers in Nigeria, representing a 3.65% increase from 2023. Of these locations, 899 Diagnostic centers, which is 95.94% of all Diagnostic centers in Nigeria, are single-owner operations, while the remaining 38, 4.06%, are part of larger brands. The top three states with the most Diagnostic centers are Lagos, with 256 Diagnostic centers; Federal Capital Territory, with 104 Diagnostic centers; and Enugu State, with 72 Diagnostic centers.
With the rising burden of malaria, HIV, and tuberculosis, the demand for accurate and timely diagnostic services is surging. The increased availability of diagnostic centers, particularly in urban and semi-urban areas, has improved healthcare accessibility and reduced patient turnaround times, thereby boosting the adoption of IVD technologies. Establishing private labs such as 54gene and Lifebank and public initiatives under the Nigeria Centre for Disease Control (NCDC) has increased testing capacity for COVID-19 and Lassa fever. These centers rely on molecular diagnostics, immunoassays, and rapid test kits. Collaborations with international partners have led to capacity-building and technology transfer. Expansion of diagnostic capabilities improves accurate diagnosis, disease monitoring, supporting public health responses, and shaping healthcare policies contribute to market growth.
Through the Nigerian Center for Disease Control (NCDC) and the Ministry of Health, the government promotes public health campaigns targeting malaria, HIV/AIDS, and tuberculosis. These campaigns emphasize early detection, prevention, and management, encouraging more people to seek diagnostic testing. As awareness grows, healthcare providers and diagnostic centers are adopting advanced IVD technologies to meet the rising demand for reliable and rapid tests. Nationwide HIV screening programs supported by government initiatives have increased the need for efficient in-vitro diagnostic kits.
Partnerships with international health organizations and government subsidies help improve access to these diagnostic tools, especially in rural and underserved areas. This supportive environment attracts investments from diagnostic companies aiming to develop and distribute innovative testing solutions tailored to local needs. By creating sustained demand for diagnostic innovations, government-driven awareness campaigns are expected to create future growth opportunities for the Nigeria infectious disease .
Key segments that contributed to the derivation of the Infectious disease in-vitro diagnostics market analysis are application, end user, and geography.
The Nigeria Infectious Disease In-vitro Diagnostics Marketis expanding steadily, fueled by a high burden of communicable diseases such as HIV/AIDS, malaria, tuberculosis, and hepatitis. With a growing population and increasing demand for early and accurate disease detection, diagnostic technologies, remarkably rapid tests, and point-of-care diagnostics are being adopted. Urban areas are witnessing better penetration due to improved healthcare infrastructure, while rural areas remain underserved but represent significant growth potential. Government health initiatives, international donor funding, and a gradual shift toward localized manufacturing and public-private partnerships support the market. However, challenges such as limited diagnostic labs, stringent regulations, and insufficient skilled personnel persist. Overall, the sector holds strong potential for investment and innovation, particularly in portable and affordable diagnostic solutions.
The regional trends and factors influencing the Nigeria Infectious Disease In-vitro Diagnostics Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Nigeria Infectious Disease In-vitro Diagnostics Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.
| Report Attribute | Details |
|---|---|
| Market size in 2024 | US$ 41.04 Million |
| Market Size by 2031 | US$ 59.67 Million |
| Global CAGR (2024 - 2031) | 5.5% |
| Historical Data | 2021-2022 |
| Forecast period | 2024-2031 |
| Segments Covered |
By Application
|
| Regions and Countries Covered | Nigeria
|
| Market leaders and key company profiles |
The Nigeria Infectious Disease In-vitro Diagnostics Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the Nigeria Infectious Disease In-vitro Diagnostics Market are:
Disclaimer: The companies listed above are not ranked in any particular order.
The Nigeria Infectious Disease In-vitro Diagnostics Market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the key developments in the market are listed below:
The "Nigeria Infectious Disease In-vitro Diagnostics Market Size and Forecast (2021–2031)" report provides a detailed analysis of the market covering below areas:
The increasing number of diagnostic centers and strategic developments by key players fuel the market growth.
The market value is expected to reach US$ 59.67 million by 2031.
Abbott Laboratories, F. Hoffmann-La Roche Ltd, Becton Dickinson and Co, Sysmex Corp, bioMerieux SA, Bio-Rad Laboratories Inc, QIAGEN NV, QuidelOrtho Corp, Bruker Corp are key players in the market.
Malaria dominated the market in 2024.
Technological advancements are expected to emerge as a prime trend in the market in the coming years.
The market is expected to register a CAGR of 5.5% during 2024–2031.